

Helsinki, 17 May 2024

## Addressee(s)

Registrant as listed in Appendix 3 of this decision

# Date of submission of the dossier subject to this decision 05 April 2018

## Registered substance subject to this decision ("the Substance")

Substance name: 2-[2-[4-[2-(4-cyanophenyl)vinyl]phenyl]vinyl]benzonitrile

EC/List number: 235-834-6

**Decision number:** Please refer to the REACH-IT message which delivered this

communication (in format CCH-D-XXXXXXXXXXXXXXX/F)

#### **DECISION ON A COMPLIANCE CHECK**

Under Article 41 of Regulation (EC) No 1907/2006 (REACH), you must submit the information listed below by **24 November 2025**.

Requested information must be generated using the Substance unless otherwise specified.

## Information required from all the Registrants subject to Annex VII of REACH

1. Growth inhibition study on aquatic plants (Annex VII, Section 9.1.2.; test method: EU C.3/OECD TG 201).

The reasons for the request(s) are explained in Appendix 1.

## Information required depends on your tonnage band

You must provide the information listed above for all REACH Annexes applicable to you in accordance with Articles 10(a) and 12(1) of REACH. The addressee of the decision and its corresponding information requirements based on registered tonnage band are listed in Appendix 3.

## How to comply with your information requirements

To comply with your information requirements, you must submit the information requested by this decision in an updated registration dossier by the deadline indicated above. You must also **update the chemical safety report, where** relevant, including any changes to classification and labelling, based on the newly generated information.

You must follow the general requirements for testing and reporting new tests under REACH, see Appendix 4.

## Appeal

This decision, when adopted under Article 51 of REACH, may be appealed to the Board of Appeal of ECHA within three months of its notification to you. Please refer to <a href="http://echa.europa.eu/regulations/appeals">http://echa.europa.eu/regulations/appeals</a> for further information.



## Failure to comply

If you do not comply with the information required by this decision by the deadline indicated above, ECHA will notify the enforcement authorities of your Member State.

Authorised<sup>1</sup> under the authority of Mike Rasenberg, Director of Hazard Assessment

Appendix 1: Reasons for the request(s)

Appendix 2: Procedure

Appendix 3: Addressees of the decision and their individual information requirements

Appendix 4: Conducting and reporting new tests under REACH

<sup>&</sup>lt;sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

## Confidential



## Appendix 1: Reasons for the request(s)

Reas	ons related to the information under Annex VII of REACH	4
1.	Growth inhibition study aquatic plants	4
Refe	rences	6



#### Reasons related to the information under Annex VII of REACH

## 1. Growth inhibition study aquatic plants

Growth inhibition study on aquatic plants is an information requirement under Annex VII to REACH (Section 9.1.2.).

## 1.1. Information provided

- You have adapted this information requirement by using Column 2 of Annex VII, Section 9.1.2. To support the adaptation, you have provided the following information:
  - (i) based on the hydrophobic nature of the Substance, i.e. its low solubility and high log K<sub>ow</sub> indicates that aquatic toxicity is unlikely to occur
  - (ii) "existing available data for the toxicity of chemical to aquatic invertebrates and algae indicates that's no effect were observed at 0.01 mg/l as the chemical was not dissolved in water"

## 1.2. Assessment of the information provided

- Under Annex VII, Section 9.1.2., Column 2, first indent, the study may be omitted if aquatic toxicity is unlikely, for instance if the Substance is highly insoluble in water. Guidance on IRs and CSA, Section R.7.8.5 explains that there is no scientific basis to define a cut off limit for solubility below which toxicity is unlikely. Therefore, the justification must demonstrate very low water solubility and low likelihood to cross biological membranes. For the latter, the indicators used for low likelihood of a high bioaccumulation potential (Guidance on IRs and CSA, Figure R.11-4) must be considered, including:
  - physico-chemical indicators of hindered uptake due to large molecular size (e.g.  $D_{max} > 17.4$  Å and molecular weight (MW) > 1100 or MML > 4.3 nm) or high octanol-water partition coefficient (Log  $K_{ow} > 10$ ) or low potential for mass storage (octanol solubility (mg/L) < 0.002 x MW), and
  - supporting experimental evidence of hindered uptake (no chronic toxicity for mammals and birds, no chronic ecotoxicity, no uptake in mammalian toxicokinetic studies, very low uptake after chronic exposure).
- 4 Unless it can reliably be demonstrated that aquatic toxicity is unlikely to occur, the Substance must be considered as poorly water soluble.
- 5 Your registration dossier provides:
  - information on the solubility of the Substance in water (0.019-0.024 mg/L based on experimental data with OECD TG 105 and QSAR;
  - a molecular weight of the Substance of ca. 332
  - a claim of low likelihood to cause toxicity based on high insolubility in water as well as partition coefficient of 6.1
  - no further justification on the low likelihood of the Substance to cross biological membranes based on hindered uptake of the Substance. For example the "existing" toxicity data to aquatic invertebrates or algae with the Substance you refer to is not provided.
- 6 Even though the water solubility of the Substance is low, the following does not support your justification:

#### Confidential



- the physico-chemical indicators provided do not support your conclusion of hindered uptake because the molecular weight of the Substance is not greater than 1100 and its logKow is not above 10;
- no evidence based on e.g. experimental data on toxicokinetics with the Substance is provided to demonstrate the lack of absorption and thus systemic espousre.
- You have not demonstrated that toxicity is unlikely to occur and your adaptation is rejected and the Substance must be considered as poorly water soluble.
- 8 Therefore, the information requirement is not fulfilled.

## 1.3. Study design

- The Substance is difficult to test due to the low water solubility 0.024 mg/L. The OECD TG 201 specifies that, for difficult to test substances, you must consider the approach described in the OECD GD 23 or other approaches, if more appropriate for your substance. In all cases, the approach selected must be justified and documented. Due to the properties of Substance, it may be difficult to achieve and maintain the desired exposure concentrations. Therefore, you must monitor the test concentration(s) of the Substance throughout the exposure duration and report the results. If it is not possible to demonstrate the stability of exposure concentrations (i.e. measured concentration(s) not within 80-120% of the nominal concentration(s)), you must express the effect concentration based on measured values as described in OECD TG 211. In case a dose-response relationship cannot be established (no observed effects), you must demonstrate that the approach used to prepare test solutions was adequate to maximise the concentration of the Substance in the test solution.
- 10 In your comments to the draft decision, you agree to perform the requested study.



#### References

The following documents may have been cited in the decision.

# Guidance on information requirements and chemical safety assessment (Guidance on IRs & CSA)

- Chapter R.4 Evaluation of available information; ECHA (2011). Chapter R.6 QSARs, read-across and grouping; ECHA (2008).
  - Appendix to Chapter R.6 for nanoforms; ECHA (2019).
- Chapter R.7a Endpoint specific guidance, Sections R.7.1 R.7.7; ECHA (2017).

  Appendix to Chapter R.7a for nanomaterials; ECHA (2017).
- Chapter R.7b Endpoint specific guidance, Sections R.7.8 R.7.9; ECHA (2017).

  Appendix to Chapter R.7b for nanomaterials; ECHA (2017).
- Chapter R.7c Endpoint specific guidance, Sections R.7.10 R.7.13; ECHA (2017). Appendix to Chapter R.7a for nanomaterials; ECHA (2017).
  - Appendix R.7.13-2 Environmental risk assessment for metals and metal compounds; ECHA (2008).
- Chapter R.11 PBT/vPvB assessment; ECHA (2017).
- Chapter R.16 Environmental exposure assessment; ECHA (2016).

Guidance on data-sharing; ECHA (2017).

Guidance for monomers and polymers; ECHA (2023).

Guidance on intermediates; ECHA (2010).

All guidance documents are available online: <a href="https://echa.europa.eu/guidance-">https://echa.europa.eu/guidance-</a>

documents/guidance-on-reach

### Read-across assessment framework (RAAF)

RAAF, 2017 Read-across assessment framework (RAAF); ECHA (2017). RAAF UVCB, 2017 Read-across assessment framework (RAAF) – considerations on

multi- constituent substances and UVCBs; ECHA (2017).

## The RAAF and related documents are available online:

 $\frac{https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across$ 

## **OECD Guidance documents (OECD GDs)**

OECD GD 23	Guidance document on aquatic toxicity testing of difficult
	substances and mixtures; No. 23 in the OECD series on testing and
	assessment, OECD (2019).
OECD GD 29	Guidance document on transformation/dissolution of metals and
	metal compounds in aqueous media; No. 29 in the OECD series on
	testing and assessment, OECD (2002).
OECD GD 150	Revised guidance document 150 on standardised test guidelines for
	evaluating chemicals for endocrine disruption; No. 150 in the OECD
	series on testing and assessment, OECD (2018).
OECD GD 151	Guidance document supporting OECD test guideline 443 on the
	extended one-generation reproductive toxicity test; No. 151 in the

OECD series on testing and assessment, OECD (2013).



## **Appendix 2: Procedure**

This decision does not prevent ECHA from initiating further compliance checks at a later stage on the registrations present.

ECHA followed the procedure detailed in Articles 50 and 51 of REACH.

The compliance check was initiated on 13 March 2023.

The deadline of the decision is set based on standard practice for carrying out OECD TG tests. It has been exceptionally extended by 6 months from the standard deadline granted by ECHA to take into account currently longer lead times in contract research organisations.

ECHA notified you of the draft decision and invited you to provide comments.

As a result of one or more changes of registration tonnage band or registration type, the requests 2 – 11 of the draft decision, addressing data gaps for information requirements listed in or triggered at Annex VIII, were removed from the decision.

The deadline was accordingly reduced from 51 to 15 months reflecting the time that is normally needed for the conduct and submission of the remaining test(s) that are requested in this decision.

In your comments you agreed to the draft decision concerning requests applicable to Annex VII information requirements. ECHA took your comments into account and did not amend those request(s).

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.



# Appendix 3: Addressee(s) of this decision and their corresponding information requirements

In accordance with Articles 10(a) and 12(1) of REACH, the information requirements for individual registrations are defined as follows:

- the information specified in Annex VII to REACH, for registration at 1-10 tonnes per year (tpa), or as a transported isolated intermediate in quantity above 1000 tpa;
- the information specified in Annexes VII and VIII to REACH, for registration at 10-100 tpa;
- the information specified in Annexes VII, VIII and IX to REACH, for registration at 100-1000 tpa;
- the information specified in Annexes VII to X to REACH, for registration at more than 1000 tpa.

Registrant Name	Registration number	Highest REACH Annex applicable to you

Where applicable, the name of a third-party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.



## Appendix 4: Conducting and reporting new tests for REACH purposes

#### 1. Requirements when conducting and reporting new tests for REACH purposes

### 1.1 Test methods, GLP requirements and reporting

- (1) Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.
- (2) Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.
- (3) Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries (https://echa.europa.eu/practical-guides).
- (4) Under the introductory part of Annexes VII/VIII/IX/X to REACH, where a test method offers flexibility in the study design, for example in relation to the choice of dose levels or concentrations, the chosen study design must ensure that the data generated are adequate for hazard identification and risk assessment.

#### 1.2 Test material

(1) Selection of the Test material(s)

The Test Material used to generate the new data must be selected taking into account the following:

- the impact of each constituent/impurity on the test results for the endpoint to be assessed. For example, if a constituent/impurity of the Substance is known to have an impact on (eco)toxicity, the selected Test Material must contain that constituent/impurity.
- (2) Information on the Test Material needed in the updated dossier
- You must report the composition of the Test Material selected for each study, under the "Test material information" section, for each respective endpoint study record in IUCLID.
- The reported composition must include all constituents of each Test Material and their concentration values.

With that detailed information, ECHA can confirm whether the Test Material is relevant for the Substance.

Technical instructions on how to report the above is available in the manual on How to prepare registration and PPORD dossiers (<a href="https://echa.europa.eu/manuals">https://echa.europa.eu/manuals</a>).